Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.88 |
| ▸ | TGM2 | P21980 | 1/20 | 0.68 |
| ▸ | FOLH1 | Q04609 | 6/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.61 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.55 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.55 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL125577 | 1.00 | HTT (0.88) | HTTTGM2FOLH1LMNASMN1; SMN2 | |
| SCHEMBL8674198 | 1.00 | HTT (0.88) | HTTTGM2FOLH1LMNASMN1; SMN2 | |
| SCHEMBL2876850 | 1.00 | HTT (0.88) | HTTTGM2FOLH1LMNASMN1; SMN2 | |
| SCHEMBL3693087 | 1.00 | HTT (0.88) | HTTTGM2FOLH1LMNASMN1; SMN2 | |
| SCHEMBL3287016 | 1.00 | HTT (0.88) | HTTTGM2FOLH1LMNASMN1; SMN2 | |
| SCHEMBL3694316 | 1.00 | HTT (0.88) | HTTTGM2FOLH1LMNASMN1; SMN2 | |
| SCHEMBL4857273 | 1.00 | HTT (0.88) | HTTTGM2FOLH1LMNASMN1; SMN2 | |
| SCHEMBL4858734 | 1.00 | HTT (0.88) | HTTTGM2FOLH1LMNASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL4438046 | 0.98 | HTT (0.86) | HTTTGM2FOLH1LMNASMN1; SMN2 | |
| SCHEMBL879577 | 0.98 | HTT (0.91) | HTTTGM2FOLH1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12522612-B2 | PDE4 inhibitors, pharmaceutical compositions, and therapeutic applications | BIOTHERYX INC. (US) | 2026-01-13 | — | — | US | disclosed |
| US-20240124418-A1 | PDE4 DEGRADERS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX INC (US) | 2024-04-18 | — | — | US | disclosed |
| CN-117203196-A | PDE4 degrading agents, pharmaceutical compositions and therapeutic applications | 拜欧斯瑞克斯公司 | 2023-12-08 | — | — | CN | disclosed |
| EP-4259621-A1 | PDE4 DEGRADERS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | Biotheryx, Inc. (US) | 2023-10-18 | — | — | EP | disclosed |
| US-20230071529-A1 | PDE4 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. (US) | 2023-03-09 | — | — | US | disclosed |
| EP-4073074-A1 | PDE4 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | Biotheryx, Inc. (US) | 2022-10-19 | — | — | EP | disclosed |
| WO-2022132603-A1 | PDE4 DEGRADERS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. (US) | 2022-06-23 | — | — | WO | disclosed |
| WO-2021119571-A1 | PDE4 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. (US) | 2021-06-17 | — | — | WO | disclosed |
| US-10919926-B2 | Compound or salt thereof, natural killer T cell activator, and pharmaceutical composition | KEIO UNIVERSITY (JP) | 2021-02-16 | — | — | US | disclosed |
| US-10919926-B2 | Compound or salt thereof, natural killer T cell activator, and pharmaceutical composition | KEIO UNIVERSITY (JP) | 2021-02-16 | — | — | US | disclosed |
| EP-1131326-B1 | PHOSPHOLIPID DERIVATIVES OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS | DPHARM LTD (IL) | 2003-05-07 | — | — | EP | disclosed |
| EP-1029869-B1 | Endothelin converting enzyme inhibitors | WELLCOME FOUND (GB) | 2003-04-23 | — | — | EP | disclosed |
| EP-1131326-A4 | PHOSPHOLIPID DERIVATIVES OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS | DPHARM LTD (IL) | 2002-03-27 | — | — | EP | disclosed |
| WO-2002018946-A2 | IMMOBILISED PHOSPHATIDIC ACID PROBE | THE BABRAHAM INSTITUTE (GB) | 2002-03-07 | — | — | WO | disclosed |
| EP-1131326-A1 | PHOSPHOLIPID DERIVATIVES OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS | D-Pharm Limited (IL) | 2001-09-12 | — | — | EP | disclosed |
| US-6235717-B1 | Pharmaceutical compounds | GLAXO WELLCOME INC. | 2001-05-22 | — | — | US | disclosed |
| EP-1029869-A1 | Endothelin converting enzyme inhibitors | THE WELLCOME FOUNDATION LIMITED (GB) | 2000-08-23 | — | — | EP | disclosed |
| WO-2000031083-A1 | PHOSPHOLIPID DERIVATIVES OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS | D-PHARM LIMITED (IL) | 2000-06-02 | — | — | WO | disclosed |
| EP-0677059-A1 | ENDOTHELIN CONVERTING ENZYME INHIBITORS | THE WELLCOME FOUNDATION LIMITED (GB) | 1995-10-18 | — | — | EP | disclosed |
| WO-1994015956-A1 | ENDOTHELIN CONVERTING ENZYME INHIBITORS | THE WELLCOME FOUNDATION LIMITED (GB) | 1994-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230071529-A1 | PDE4 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | PDE4A, PDE4B, PDE2A | HTT 3131/4885TGM2 1468/4885FOLH1 587/4885 |
| US-10919926-B2 | Compound or salt thereof, natural killer T cell activator, and pharmaceutical composition | CD4, NFATC1, PBK | HTT 2847/4885TGM2 4387/4885FOLH1 2976/4885 |
| US-20240124418-A1 | PDE4 DEGRADERS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | PDE4A, PDE4B, PDE12 | HTT 1605/4885TGM2 2045/4885FOLH1 855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.